A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Latest Information Update: 11 Oct 2024
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms TOURMALINE-MM1
- Sponsors Takeda; Takeda Oncology
- 19 Dec 2022 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 24 Feb 2022 Status changed from active, no longer recruiting to completed.
- 09 Feb 2022 This trial has been completed in Sweden, according to European Clinical Trials Database record.